Cargando…
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
BACKGROUND: Albuminuria is a marker of inflammation and an independent predictor of cardiovascular morbidity and mortality. The current study evaluated whether eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation attenuates progression of albuminuria in subjects with coronary a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586259/ https://www.ncbi.nlm.nih.gov/pubmed/28710178 http://dx.doi.org/10.1161/JAHA.116.004740 |
_version_ | 1783261780306296832 |
---|---|
author | Elajami, Tarec K. Alfaddagh, Abdulhamied Lakshminarayan, Dharshan Soliman, Michael Chandnani, Madhuri Welty, Francine K. |
author_facet | Elajami, Tarec K. Alfaddagh, Abdulhamied Lakshminarayan, Dharshan Soliman, Michael Chandnani, Madhuri Welty, Francine K. |
author_sort | Elajami, Tarec K. |
collection | PubMed |
description | BACKGROUND: Albuminuria is a marker of inflammation and an independent predictor of cardiovascular morbidity and mortality. The current study evaluated whether eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation attenuates progression of albuminuria in subjects with coronary artery disease. METHODS AND RESULTS: Two‐hundred sixty‐two subjects with stable coronary artery disease were randomized to either Lovaza (1.86 g of EPA and 1.5 g of DHA daily) or no Lovaza (control) for 1 year. Percent change in urine albumin‐to‐creatinine ratio (ACR) was compared. Mean (SD) age was 63.3 (7.6) years; 17% were women and 30% had type 2 diabetes mellitus. In nondiabetic subjects, no change in urine ACR occurred in either the Lovaza or control groups. In contrast, ACR increased 72.3% (P<0.001) in diabetic subjects not receiving Lovaza, whereas those receiving Lovaza had no change. In diabetic subjects on an angiotensin‐converting enzyme‐inhibitor or angiotensin‐receptor blocker, those receiving Lovaza had no change in urine ACR, whereas those not receiving Lovaza had a 64.2% increase (P<0.001). Change in ACR was directly correlated with change in systolic blood pressure (r=0.394, P=0.01). CONCLUSIONS: EPA and DHA supplementation attenuated progression of albuminuria in subjects with type 2 diabetes mellitus and coronary artery disease, most of whom were on an angiotensin‐converting enzyme‐inhibitor or angiotensin‐receptor blocker. Thus, EPA and DHA supplementation should be considered as additional therapy to an angiotensin‐converting enzyme‐inhibitor or angiotensin‐receptor blocker in subjects with type 2 diabetes mellitus and coronary artery disease. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01624727. |
format | Online Article Text |
id | pubmed-5586259 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55862592017-09-11 Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease Elajami, Tarec K. Alfaddagh, Abdulhamied Lakshminarayan, Dharshan Soliman, Michael Chandnani, Madhuri Welty, Francine K. J Am Heart Assoc Original Research BACKGROUND: Albuminuria is a marker of inflammation and an independent predictor of cardiovascular morbidity and mortality. The current study evaluated whether eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation attenuates progression of albuminuria in subjects with coronary artery disease. METHODS AND RESULTS: Two‐hundred sixty‐two subjects with stable coronary artery disease were randomized to either Lovaza (1.86 g of EPA and 1.5 g of DHA daily) or no Lovaza (control) for 1 year. Percent change in urine albumin‐to‐creatinine ratio (ACR) was compared. Mean (SD) age was 63.3 (7.6) years; 17% were women and 30% had type 2 diabetes mellitus. In nondiabetic subjects, no change in urine ACR occurred in either the Lovaza or control groups. In contrast, ACR increased 72.3% (P<0.001) in diabetic subjects not receiving Lovaza, whereas those receiving Lovaza had no change. In diabetic subjects on an angiotensin‐converting enzyme‐inhibitor or angiotensin‐receptor blocker, those receiving Lovaza had no change in urine ACR, whereas those not receiving Lovaza had a 64.2% increase (P<0.001). Change in ACR was directly correlated with change in systolic blood pressure (r=0.394, P=0.01). CONCLUSIONS: EPA and DHA supplementation attenuated progression of albuminuria in subjects with type 2 diabetes mellitus and coronary artery disease, most of whom were on an angiotensin‐converting enzyme‐inhibitor or angiotensin‐receptor blocker. Thus, EPA and DHA supplementation should be considered as additional therapy to an angiotensin‐converting enzyme‐inhibitor or angiotensin‐receptor blocker in subjects with type 2 diabetes mellitus and coronary artery disease. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01624727. John Wiley and Sons Inc. 2017-07-14 /pmc/articles/PMC5586259/ /pubmed/28710178 http://dx.doi.org/10.1161/JAHA.116.004740 Text en © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Elajami, Tarec K. Alfaddagh, Abdulhamied Lakshminarayan, Dharshan Soliman, Michael Chandnani, Madhuri Welty, Francine K. Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease |
title | Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease |
title_full | Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease |
title_fullStr | Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease |
title_full_unstemmed | Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease |
title_short | Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease |
title_sort | eicosapentaenoic and docosahexaenoic acids attenuate progression of albuminuria in patients with type 2 diabetes mellitus and coronary artery disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586259/ https://www.ncbi.nlm.nih.gov/pubmed/28710178 http://dx.doi.org/10.1161/JAHA.116.004740 |
work_keys_str_mv | AT elajamitareck eicosapentaenoicanddocosahexaenoicacidsattenuateprogressionofalbuminuriainpatientswithtype2diabetesmellitusandcoronaryarterydisease AT alfaddaghabdulhamied eicosapentaenoicanddocosahexaenoicacidsattenuateprogressionofalbuminuriainpatientswithtype2diabetesmellitusandcoronaryarterydisease AT lakshminarayandharshan eicosapentaenoicanddocosahexaenoicacidsattenuateprogressionofalbuminuriainpatientswithtype2diabetesmellitusandcoronaryarterydisease AT solimanmichael eicosapentaenoicanddocosahexaenoicacidsattenuateprogressionofalbuminuriainpatientswithtype2diabetesmellitusandcoronaryarterydisease AT chandnanimadhuri eicosapentaenoicanddocosahexaenoicacidsattenuateprogressionofalbuminuriainpatientswithtype2diabetesmellitusandcoronaryarterydisease AT weltyfrancinek eicosapentaenoicanddocosahexaenoicacidsattenuateprogressionofalbuminuriainpatientswithtype2diabetesmellitusandcoronaryarterydisease |